Does the media favor LNTH or RXRX?

In the previous week, Lantheus had 2 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 9 mentions for Lantheus and 7 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.68 beat Lantheus' score of 0.46 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Recursion Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RYTM or RXRX?

In the previous week, Recursion Pharmaceuticals had 1 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 7 mentions for Recursion Pharmaceuticals and 6 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.71 beat Recursion Pharmaceuticals' score of 0.68 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Recursion Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RXRX or PTCT?

In the previous week, PTC Therapeutics had 10 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 17 mentions for PTC Therapeutics and 7 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.68 beat PTC Therapeutics' score of 0.53 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PTC Therapeutics 8 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RXRX or MIRM?

In the previous week, Recursion Pharmaceuticals had 2 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 7 mentions for Recursion Pharmaceuticals and 5 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.10 beat Recursion Pharmaceuticals' score of 0.68 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CNTA or RXRX?

In the previous week, Recursion Pharmaceuticals had 2 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 7 mentions for Recursion Pharmaceuticals and 5 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.73 beat Recursion Pharmaceuticals' score of 0.68 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Recursion Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Recursion Pharmaceuticals (RXRX) Competitors

$3.52 +0.18 (+5.39%)

Closing price 04:00 PM Eastern

Extended Trading

$3.51 -0.01 (-0.28%)

As of 07:59 PM Eastern

Compare

RXRX vs. LNTH, RYTM, PTCT, MIRM, and CNTA

Should you buy Recursion Pharmaceuticals stock or one of its competitors? MarketBeat compares Recursion Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Recursion Pharmaceuticals include Lantheus (LNTH), Rhythm Pharmaceuticals (RYTM), PTC Therapeutics (PTCT), Mirum Pharmaceuticals (MIRM), and Centessa Pharmaceuticals (CNTA). These companies are all part of the "pharmaceutical products" industry.

How does Recursion Pharmaceuticals compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

In the previous week, Lantheus had 2 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 9 mentions for Lantheus and 7 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.68 beat Lantheus' score of 0.46 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Recursion Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has a beta of -0.03, suggesting that its stock price is 103% less volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

Lantheus has higher revenue and earnings than Recursion Pharmaceuticals. Recursion Pharmaceuticals is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.64	$233.56M	$4.15	26.46
Recursion Pharmaceuticals	$74.68M	24.98	-$644.76M	-$1.20	N/A

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 1.7% of Lantheus shares are owned by insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Lantheus has a net margin of 18.05% compared to Recursion Pharmaceuticals' net margin of -842.95%. Lantheus' return on equity of 29.32% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%

Lantheus currently has a consensus target price of $101.86, indicating a potential downside of 7.23%. Recursion Pharmaceuticals has a consensus target price of $8.10, indicating a potential upside of 130.11%. Given Recursion Pharmaceuticals' higher possible upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Lantheus beats Recursion Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Rhythm Pharmaceuticals has higher revenue and earnings than Recursion Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	39.67	-$196.54M	-$3.13	N/A
Recursion Pharmaceuticals	$74.68M	24.98	-$644.76M	-$1.20	N/A

Rhythm Pharmaceuticals presently has a consensus price target of $133.13, suggesting a potential upside of 21.20%. Recursion Pharmaceuticals has a consensus price target of $8.10, suggesting a potential upside of 130.11%. Given Recursion Pharmaceuticals' higher probable upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Recursion Pharmaceuticals had 1 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 7 mentions for Recursion Pharmaceuticals and 6 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.71 beat Recursion Pharmaceuticals' score of 0.68 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Recursion Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rhythm Pharmaceuticals has a beta of 1.91, meaning that its share price is 91% more volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market.

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Recursion Pharmaceuticals' net margin of -842.95%. Recursion Pharmaceuticals' return on equity of -54.33% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Rhythm Pharmaceuticals beats Recursion Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to PTC Therapeutics?

Recursion Pharmaceuticals (NASDAQ:RXRX) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

Recursion Pharmaceuticals has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

In the previous week, PTC Therapeutics had 10 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 17 mentions for PTC Therapeutics and 7 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.68 beat PTC Therapeutics' score of 0.53 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PTC Therapeutics	8 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PTC Therapeutics has higher revenue and earnings than Recursion Pharmaceuticals. PTC Therapeutics is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68M	24.98	-$644.76M	-$1.20	N/A
PTC Therapeutics	$1.73B	4.05	$682.64M	-$2.33	N/A

PTC Therapeutics has a net margin of -22.58% compared to Recursion Pharmaceuticals' net margin of -842.95%. Recursion Pharmaceuticals' return on equity of -54.33% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%
PTC Therapeutics	-22.58%	-362.45%	-6.76%

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 6.7% of Recursion Pharmaceuticals shares are owned by insiders. Comparatively, 5.5% of PTC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Recursion Pharmaceuticals presently has a consensus target price of $8.10, indicating a potential upside of 130.11%. PTC Therapeutics has a consensus target price of $91.36, indicating a potential upside of 8.20%. Given Recursion Pharmaceuticals' higher probable upside, research analysts plainly believe Recursion Pharmaceuticals is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Recursion Pharmaceuticals beats PTC Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Mirum Pharmaceuticals?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

Recursion Pharmaceuticals has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

Mirum Pharmaceuticals has higher revenue and earnings than Recursion Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$74.68M	24.98	-$644.76M	-$1.20	N/A
Mirum Pharmaceuticals	$569.61M	13.23	-$23.36M	-$13.61	N/A

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 6.7% of Recursion Pharmaceuticals shares are held by insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Recursion Pharmaceuticals had 2 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 7 mentions for Recursion Pharmaceuticals and 5 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 1.10 beat Recursion Pharmaceuticals' score of 0.68 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Recursion Pharmaceuticals currently has a consensus price target of $8.10, indicating a potential upside of 130.11%. Mirum Pharmaceuticals has a consensus price target of $139.80, indicating a potential upside of 13.12%. Given Recursion Pharmaceuticals' higher possible upside, equities analysts plainly believe Recursion Pharmaceuticals is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Mirum Pharmaceuticals has a net margin of -140.24% compared to Recursion Pharmaceuticals' net margin of -842.95%. Mirum Pharmaceuticals' return on equity of -11.28% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Summary

Mirum Pharmaceuticals beats Recursion Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Centessa Pharmaceuticals?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

Centessa Pharmaceuticals has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

Centessa Pharmaceuticals has higher earnings, but lower revenue than Recursion Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	$15M	417.77	-$197.53M	-$1.79	N/A
Recursion Pharmaceuticals	$74.68M	24.98	-$644.76M	-$1.20	N/A

Centessa Pharmaceuticals has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -842.95%. Recursion Pharmaceuticals' return on equity of -54.33% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 4.1% of Centessa Pharmaceuticals shares are held by company insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Centessa Pharmaceuticals presently has a consensus target price of $41.33, indicating a potential upside of 2.06%. Recursion Pharmaceuticals has a consensus target price of $8.10, indicating a potential upside of 130.11%. Given Recursion Pharmaceuticals' higher possible upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Recursion Pharmaceuticals had 2 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 7 mentions for Recursion Pharmaceuticals and 5 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 0.73 beat Recursion Pharmaceuticals' score of 0.68 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Centessa Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Recursion Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Recursion Pharmaceuticals beats Centessa Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Recursion Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RXRX vs. The Competition

Export

Metric	Recursion Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.77B	$3.02B	$6.71B	$12.24B
Dividend Yield	N/A	1.77%	2.67%	6.10%
P/E Ratio	-2.93	19.27	26.03	24.18
Price / Sales	24.98	333.24	557.66	102.02
Price / Cash	N/A	56.66	46.99	54.37
Price / Book	1.64	4.21	10.77	6.35
Net Income	-$644.76M	$64.45M	$3.57B	$337.63M
7 Day Performance	8.98%	2.24%	3.15%	-0.30%
1 Month Performance	18.92%	1.74%	2.33%	0.36%
1 Year Performance	-34.81%	26.63%	33.42%	26.94%

Recursion Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RXRX Recursion Pharmaceuticals	2.8779 of 5 stars	$3.52 +5.4%	$8.10 +130.1%	-35.3%	$1.77B	$74.68M	N/A	400	High Trading Volume
LNTH Lantheus	2.665 of 5 stars	$103.92 +0.1%	$101.86 -2.0%	+35.3%	$6.76B	$1.55B	25.04	1,193
RYTM Rhythm Pharmaceuticals	2.5073 of 5 stars	$96.79 flat	$133.13 +37.5%	+73.8%	$6.63B	$189.76M	N/A	140	Insider Trade High Trading Volume
PTCT PTC Therapeutics	2.5258 of 5 stars	$78.98 flat	$91.36 +15.7%	+72.9%	$6.55B	$1.73B	N/A	1,410	Insider Trade
MIRM Mirum Pharmaceuticals	2.2702 of 5 stars	$107.13 flat	$139.80 +30.5%	+134.0%	$6.53B	$521.31M	N/A	140	Positive News Analyst Downgrade High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RXRX) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Recursion Pharmaceuticals (RXRX) Competitors

RXRX vs. LNTH, RYTM, PTCT, MIRM, and CNTA

How does Recursion Pharmaceuticals compare to Lantheus?

Summary

How does Recursion Pharmaceuticals compare to Rhythm Pharmaceuticals?

Summary

How does Recursion Pharmaceuticals compare to PTC Therapeutics?

Summary

How does Recursion Pharmaceuticals compare to Mirum Pharmaceuticals?

Summary

How does Recursion Pharmaceuticals compare to Centessa Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX vs. The Competition

Recursion Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Recursion Pharmaceuticals (RXRX) Competitors

RXRX vs. LNTH, RYTM, PTCT, MIRM, and CNTA

How does Recursion Pharmaceuticals compare to Lantheus?

Does the media favor LNTH or RXRX?

Which has more volatility and risk, LNTH or RXRX?

Which has preferable valuation and earnings, LNTH or RXRX?

Do insiders and institutionals believe in LNTH or RXRX?

Is LNTH or RXRX more profitable?

Do analysts prefer LNTH or RXRX?

Summary

How does Recursion Pharmaceuticals compare to Rhythm Pharmaceuticals?

Which has higher valuation and earnings, RYTM or RXRX?

Do analysts rate RYTM or RXRX?

Does the media prefer RYTM or RXRX?

Which has more risk and volatility, RYTM or RXRX?

Is RYTM or RXRX more profitable?

Do institutionals & insiders have more ownership in RYTM or RXRX?

Summary

How does Recursion Pharmaceuticals compare to PTC Therapeutics?

Which has more risk and volatility, RXRX or PTCT?

Does the media favor RXRX or PTCT?

Which has better valuation & earnings, RXRX or PTCT?

Is RXRX or PTCT more profitable?

Do institutionals and insiders believe in RXRX or PTCT?

Do analysts prefer RXRX or PTCT?

Summary

How does Recursion Pharmaceuticals compare to Mirum Pharmaceuticals?

Which has more volatility & risk, RXRX or MIRM?

Which has preferable earnings & valuation, RXRX or MIRM?

Do insiders and institutionals have more ownership in RXRX or MIRM?

Does the media refer more to RXRX or MIRM?

Do analysts recommend RXRX or MIRM?

Is RXRX or MIRM more profitable?

Summary

How does Recursion Pharmaceuticals compare to Centessa Pharmaceuticals?

Which has more volatility and risk, CNTA or RXRX?

Which has stronger earnings and valuation, CNTA or RXRX?

Is CNTA or RXRX more profitable?

Do insiders & institutionals have more ownership in CNTA or RXRX?

Do analysts recommend CNTA or RXRX?

Does the media refer more to CNTA or RXRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXRX vs. The Competition

Recursion Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools